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A Novel Resveratrol Based Tubulin 
Inhibitor Induces Mitotic Arrest and 
Activates Apoptosis in Cancer Cells
Elizabeth Thomas1, Vidya Gopalakrishnan2, Mahesh Hegde1, Sujeet Kumar3, Subhas S. Karki3, 
Sathees C. Raghavan1 & Bibha Choudhary2
Resveratrol is one of the most widely studied bioactive plant polyphenols which possesses anticancer 
properties. Previously we have reported synthesis, characterization and identification of a novel 
resveratrol analog, SS28. In the present study, we show that SS28 induced cytotoxicity in several 
cancer cell lines ex vivo with an IC50 value of 3–5 μM. Mechanistic evaluation of effect of SS28 in 
non-small cell lung cancer cell line (A549) and T-cell leukemic cell line (CEM) showed that it inhibited 
Tubulin polymerization during cell division to cause cell cycle arrest at G2/M phase of the cell cycle at 
12–18 h time period. Immunofluorescence studies confirmed the mitotic arrest upon treatment with 
SS28. Besides, we show that SS28 binds to Tubulin with a dissociation constant of 0.414 ± 0.11 μM. 
Further, SS28 treatment resulted in loss of mitochondrial membrane potential, activation of Caspase 
9 and Caspase 3, leading to PARP-1 cleavage and finally cell death via intrinsic pathway of apoptosis. 
Importantly, treatment with SS28 resulted in regression of tumor in mice. Hence, our study reveals the 
antiproliferative activity of SS28 by disrupting microtubule dynamics by binding to its cellular target 
Tubulin and its potential to be developed as an anticancer molecule.
Microtubules are cytoskeletal filaments in cells composed of two proteins α and β Tubulin which are involved in 
many cellular functions such as formation of meiotic and mitotic spindle, cell motility, cell shape and transport of 
proteins and organelles1. Microtubules and their dynamics are targets of chemically diverse group of antimitotic 
compounds that are derived mostly from natural sources. Antimitotic agents inhibit cell proliferation by acting 
on the polymerization of spindle microtubules, which are essential for proper spindle function. Although the 
antimitotic drugs have been used clinically for treating diseases, the loss of efficacy over time due to development 
of resistance is considered as a major drawback2,3.
The most successful microtubule targeting drugs includes Vinca alkaloids (Vincristine, Vinblastine, 
Vinorelbine, Vindesine and Vinflunine), paclitaxel and docetaxel. Among these, Vincristine and Vinblastine 
are Tubulin binding agents, bind to the Vinca domain and inhibit Tubulin assembly4,5. In contrast, paclitaxel 
and docetaxel bind to the taxane-binding site and stabilize microtubules without increasing microtubule 
polymerisation6–8.
Resveratrol (trans-3,4′ ,5-trihydroxystilbene), a naturally occurring polyphenolic compound is highly enriched 
in the skin of red grapes, peanuts and various fruits. It has also been reported in the root of the plant, Polygonum 
cuspidatum, and an important constituent of Chinese and Japanese folk medicines9. Resveratrol has been exten-
sively investigated as a cardioprotective, anti-inflammatory, and antiaging agent10–12. In addition, studies have 
shown that resveratrol has a strong chemopreventive effect against the development of cancers of skin, breast, 
prostate and lung10,13–16. Besides, effects of resveratrol in downregulation of angiogenesis-associated genes, acti-
vation of the apoptotic pathways and induction of cell cycle arrest have also been studied17–20.
Using resveratrol as the prototype, we have recently synthesised various analogs, evaluated their effect on can-
cer cell lines and identified (E)-1,2,3-trimethoxy-5-(4-methylstyryl)benzene (6 h) (SS28) as the potent molecule21. 
In the present study we evaluate antiproliferative activity of SS28 in different cancer cells and show that SS28 treat-
ment leads to G2/M arrest. In addition, we have determined binding affinity of SS28 to purified Tubulin. Further, 
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we show that SS28 interferes with Tubulin polymerization leading to disruption of the formation of microtubule, 
which in turn leads to metaphase arrest. Eventually, SS28 treatment results in cell death by activating the intrinsic 
pathway of apoptosis.
Results
SS28 induces cytotoxicity in different cancer cell lines. Various leukemic cell lines (CEM, Reh, Molt4 
and Nalm6), human lung carcinoma cells (A549), cervical cancer cell line (HeLa), Diffuse large B cell lymphoma 
cell line (SUDHL8) and human embryonic kidney epithelial cell line (HEK293T) were used for evaluating their 
sensitivity towards SS28 (1, 5, 10 and 20 μ M). Cells treated with DMSO were used as vehicle control. Results of 
trypan blue assays showed that SS28 interfered with cell viability in a dose dependent manner (Fig. 1). Among 
the cell lines tested CEM and A549 exhibited maximum sensitivity to SS28 followed by SUDHL8, Molt4 and Reh, 
whereas Nalm6 showed moderate sensitivity after 48 h of the treatment (Fig. 1). IC50 values of SS28 in CEM and 
A549 cell line were 2.6 and 5.2 μ M, respectively, whereas in SUDHL8, Molt4, Reh and Nalm6 were 2.7, 5.1, 7.9 and 
21 μ M, respectively after 48 h of treatment (Suppl. Table 1). Among the cancer cell lines studied, HeLa cells exhib-
ited least sensitivity to SS28 (32.4 μ M) (Suppl. Table 1). Interestingly, SS28 induced only limited cytotoxicity on 
normal cell line HEK293T, compared to most of the cancer cells (Fig. 1). Besides, we also observed minimal effect 
on cell viability (48 h), when peripheral blood mononuclear cells (PBMC) were treated with SS28 with an IC50 
value > 35 μ M (Suppl. Table 1). However, when mouse embryonic fibroblast cells (MEF) were evaluated for their 
sensitivity to SS28, it exhibited significant cell death with an IC50 value 5 μ M (Suppl. Table 1). This is understand-
able as MEFs are known to proliferate efficiently and SS28 is most probably acting as a Tubulin inhibitor. Impact 
Figure 1. Effect of SS28 on cell viability in various cancer cell lines. Cells were cultured with increasing 
concentrations (1, 5, 10 and 20 μ M) of SS28 for 48 and 72 h. Trypan blue and MTT assays were performed to 
assess the cytoxicity induced by SS28. Cells treated with DMSO served as vehicle control. Different cancer cell 
lines, CEM (A), Reh (B), Molt4 (C), Nalm6 (D), SUDHL8 (E), A549 (F) 293T (G) were used for the study. Each 
experiment was repeated a minimum of three times. Error bars indicate the SEM and P value was calculated by 
comparing the mean of control group with mean of SS28 treated group, *p < 0.05, **p < 0.005, ***p < 0.0001.
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of SS28 treatment on cell proliferation was also evaluated using MTT assay. Results showed that the proliferation 
of cells was affected maximally in the case of CEM, A549, Molt4 and SUDHL8 which was followed by Reh and 
Nalm6 after 48 h of treatment (Fig. 1). Taken together, our results suggest that SS28 affected cancer cell growth in 
all leukemic cells and lung cancer cells tested.
SS28 induces G2/M cell cycle arrest. To examine whether the growth inhibition observed is due to cell 
cycle arrest followed by apoptosis, A549 and CEM cells were treated with SS28 (5 μ M for A549 and 2 μ M for CEM) 
for various time points (6, 12, 18, 24 and 30 h) and cell cycle distribution was studied by flow cytometry. Results 
showed significant accumulation of cells at G2/M phase in a time-dependent manner (6 to 24 h) and a subse-
quent increase in the sub-G1 population, indicative of apoptosis at 30 h in case of A549 (Fig. 2A; Suppl. Fig. 1A). 
Thus our result showed a prominent G2/M arrest following SS28 treatment in A549 cells.
Similarly, studies in CEM also showed a distinct G2/M arrest after 12 h of treatment, as compared to vehi-
cle control (Fig. 2B; Suppl. Fig. 1B). However, further increase in incubation resulted in elevated levels of cell 
death accounting for observed increase in sub-G1 population. Therefore, our results suggest that SS28 treatment 
resulted in cell cycle arrest at G2/M phase leading to apoptosis upon further incubation.
Effect of SS28 on mitotic spindle organization. Since we observed G2/M phase arrest during cell cycle 
analysis, we checked whether SS28 affects organisation of spindle microtubule during mitotic progression of 
cells. To investigate this, lung cancer cell line, A549 was chosen as it showed significant G2/M arrest. A549 cells 
Figure 2. Effect of SS28 on cell cycle progression and spindle microtubule formation. (A,B) Bar diagram 
summarising the % of cells in each phase of cell cycle. A549 (A) and CEM (B) cells were treated with SS28, 5 
and 2 μ M, respectively for different time points (6, 12, 18, 24 and 30 h) and cell cycle phase distribution was 
analysed by flow cytometry. DMSO treated cells served as the vehicle control. (C–F) Effect of SS28 on spindle 
microtubule formation in A549 cells. A549 cells were cultured in presence of 5 and 10 μ M of SS28 for 24 h. Cells 
were then fixed and labelled with a monoclonal α -Tubulin (green) antibody conjugated to FITC and nuclei 
stained with DAPI (blue) as described in materials and methods. (C) Table representing the metaphase arrest in 
the control and treated cells after 5 and 10 μ M of SS28 treatment. Representative fluorescence images of control 
and treated cells in duplicates. (D) SS28 treated (5 and 10 μ M) A549 cells showing bipolar spindles. (E) SS28 
treated (10 μ M) A549 cells (10X view). (F) Single cell view of secondary antibody control, primary antibody 
treated control cells and Colchicine treated cell. Images shown are DAPI, FITC and merged, respectively.
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treated with SS28 (0, 5 and 10 μ M) for 24 h were processed for immunofluorescence microscopy studies (Fig. 2C). 
Results showed that ~38% of the cells displayed abnormal spindle organisation upon treatment with 5 μ M of 
SS28 (Fig. 2C–F). Many cells had multipolar spindles, while others had aberrant bipolar spindles with misaligned 
chromosomes (Fig. 2D). Both multipolar spindles and abnormal bipolar spindles were also observed upon 10 μM 
SS28 treatment (Fig. 2C–F). The observed abnormal spindle organisation could be due to the binding of SS28 
to Tubulin, thereby preventing microtubule polymerisation. A large fraction of cells also showed chromosome 
condensation which is a characteristic feature of prometaphase stage of mitosis (Fig. 2E).
Further we used Colchicine treated A549 cells as a positive control for the study (Fig. 2F). Colchicine is known 
to destabilise microtubule assembly by binding to Tubulin19,22. Upon treatment with Colchicine, expected chro-
mosome condensation and metaphase arrest was observed as compared to untreated cells (Fig. 2F). Thus, the 
compound SS28 significantly affected the microtubule formation leading to chromosome condensation, which 
was comparable to that of Colchicine.
SS28 affects the Tubulin polymerisation. Cell based Tubulin polymerisation assay was performed to 
check whether SS28 indeed affects the Tubulin polymerisation. Results showed that the pellet fraction containing 
the polymerised Tubulin decreased upon treatment with SS28 in a concentration dependent manner (Fig. 3A). 
In contrast, the supernatant fraction containing depolymerised microtubules remained equal in all the cases 
irrespective of the concentration (Fig. 3A). This suggests that SS28 inhibited the Tubulin polymerisation at a 
concentration of 2 μ M onwards due to its binding to Tubulin.
To gain insights about SS28 interaction with Tubulin, docking studies were carried out using 
Autodock4.2.program. Results showed that, methyl benzene group of SS28 can fit in the methoxytropone ring 
(ring C) of colchicine binding site of Tubulin (Fig. 3B,C). Besides the trimethoxy benzene group of SS28 is 
involved in the hydrogen bond interactions with Lys 254 and Asn 101 of Tubulin chain with a favourable binding 
energy of − 6.83 kcal/mol (Fig. 3C). Hence, docking studies revealed potential interaction of SS28 with Tubulin 
(Fig. 3C). Thus, our biochemical data in conjunction with docking studies suggest that SS28 can indeed target 
Tubulin within the cells.
Figure 3. Docking studies showing SS28 interaction with Tubulin in colchicine binding site and the effect 
of SS28 on microtubule dynamics. (A) CEM cells were treated with SS28 (2, 5 and 10 μ M) and processed for 
the microtubule assembly assay. Supernatant fractions were resolved in 8% SDS-PAGE. The pellet fractions were 
immunoblotted using α - Tubulin antibody and quantified. (B) Structure of SS28. (C) Docked pose of SS28 with 
Tubulin. SS28 can interact with the colchicine binding pocket of Tubulin with the hydrogen bond interaction 
with Lys 254 and Asn 101. SS28 represented in red and colchicine in blue colour.
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SS28 can bind to Tubulin. To test whether SS28 can directly bind to purified Tubulin, purified protein 
was incubated with increasing concentration of ligand (500 pM, 1, 10, 100, 1000 nM) in PEM buffer and circu-
lar dichroism (CD) was performed. Results showed a shift in the spectrum when SS28 was added from as low 
as 500 pM (Fig. 4A). Thus, addition of SS28 to Tubulin significantly increased the molar ellipticity suggesting 
alteration in the secondary structure of Tubulin. Further, fluorescence studies were conducted to evaluate the 
binding affinity of SS28 to Tubulin. SS28 exhibited fluorescence in aqueous solution, with an emission maximum 
at 399 nm. The binding to purified Tubulin results in an induction of fluorescence in a concentration dependent 
manner (Fig. 4B). The change in fluorescence of SS28 was used to determine both association and dissociation. 
The double reciprocal plot of fluorescence data yielded a dissociation constant (Kd) of 0.414 ± 0.11 μ M with a 
binding ratio 1:1 (Fig. 4C).
SS28 treatment did not result in ROS production. Intracellular ROS production was tested follow-
ing treatment with SS28 (2 μ M) in CEM cells by flow cytometry after staining with H2DCFDA (Suppl. Fig. 2A). 
Results did not show generation of ROS when tested for an incubation period as early as 5 min or at later time 
points (Suppl. Fig. 2). In contrast, the cells treated with H2O2 showed a distinct ROS production which served as 
positive control (Suppl. Fig. 2). Hence, our results suggest that SS28 treatment does not result in ROS production 
indicating that cell death is not caused by oxidative stress.
SS28 treatment affected the mitochondrial membrane potential. Mitochondrial membrane 
potential plays an important role in triggering apoptosis by regulating the membrane permeability23. Therefore, 
we checked the effect of SS28 treatment on mitochondrial membrane potential in CEM cells using JC-1 staining 
followed by flow cytometry (Fig. 5A). The JC-1 dye, due to an inherent positive charge enters the mitochondrial 
matrix due to the negative charge established by the intact mitochondrial membrane potential. When intact mito-
chondrial membrane potential is absent due to a chemical treatment, JC-1 accumulates in the cytoplasm in mon-
omeric form characterized by green fluorescence. Upon treatment with SS28, a concentration dependant increase 
in the green fluoresced cells was observed in contrast to control cells which exhibited maximum red fluorescence 
(Fig. 5A,B). Hence our results suggest the loss of mitochondrial membrane potential upon treatment with SS28.
Treatment with SS28 resulted in apoptosis rather than necrosis. Previous studies suggested that 
microtubule-inhibiting agents cause G2/M phase arrest followed by apoptosis24,25. Hence, we used Annexin 
V-FITC/PI double-staining method to study apoptosis and necrosis following exposure to SS28 (5 and 10 μ M for 
48 h) in CEM cells. Results showed that SS28 induced apoptosis in a concentration dependent manner (Fig. 5C). 
At 5 μ M, 39.8% of cells were in late apoptosis while 28.2% in early apoptotic stage, whereas they were 46.9% and 
32.9% respectively, when treated with 10 μ M of SS28 (Fig. 5C,D). However, we did not observe any cells under-
going necrosis (Fig. 5C).
SS28 treatment lead to alteration in the expression levels of cell cycle and apoptotic proteins. 
In order to study the mechanism by which SS28 induces cell cycle arrest and apoptosis, we studied the expression 
levels of some of the cell cycle and apoptotic markers. To accomplish this, CEM and A549 cells were treated with 
SS28 (5 μ M for 24, 48 and 72 h), cell lysates were prepared and used for western blotting studies. The level of 
Cyclin B1, a key regulator of cells entry into mitosis, was increased at 48 h time point in CEM cells followed by a 
decrease at 72 h (Fig. 6A,B). However, in case of A549 cell line, the Cyclin B1 level was maintained throughout the 
time period, but with a moderate decrease at 48 h (Fig. 6C,D). The expression level of Cdk6 was increased at 24 h 
followed by a decrease at 48 and 72 h in both the cell lines tested (Fig. 6).
To further investigate the underlying mechanism of action of SS28 on cancer cell lines, we examined the 
possible involvement of apoptotic proteins. Caspase 9, an indicator of intrinsic pathway of apoptosis, showed an 
Figure 4. Evaluation of binding affinity of SS28 to Tubulin. (A) Circular dichroism studies were performed 
at 200–260 nm (4 °C) on a JASCO J-810 spectropolarimeter. The spectra of Tubulin alone (1 μ M) in PEM buffer 
and in presence of increasing concentration of SS28 were recorded. Spectra of buffer containing corresponding 
concentrations of DMSO were subtracted from experimental data and presented. (B) Evaluation of change in 
fluorescence intensity when increasing concentration of Tubulin was added to SS28. Emission spectra of SS28 
alone (10 μ M) or with increasing concentration of Tubulin (10, 25, 50, 100, 500 and 1000 nM) were recorded 
following incubation at 30 °C for 30 min. The fluorescence intensities were plotted against the wavelength.  
(C) The double reciprocal plot of SS28 binding to Tubulin. X axis indicates the concentration of Tubulin and  
Y axis represents the differences in the fluorescence intensity.
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increase in the cleaved Caspase 9 level (Fig. 6). Another marker of apoptosis, Caspase 3 also showed activation 
in both the cancer cells, further suggesting activation of apoptosis (Fig. 6). Besides, we also observed activation 
of PARP1 upon treatment with SS28 in CEM cells. Since activation of apoptosis was dependent on Caspase 3, 
we checked the expression levels of p53. Results showed an upregulation of p53 at 24 h time point followed by 
a decrease in the later time points (Fig. 6A,B). However, in A549 cells the expression levels of p73, which is also 
involved in the induction of apoptosis remained same (Fig. 6C,D).
SS28 showed inhibition of tumor progression in mice. In order to examine the in vivo effect of SS28 
on tumor cell death in a mouse model, tumor was induced in BALB/c mice using EAC cells. A total of 10 mice 
were used per batch which included 5 tumor bearing mice (control) and 5 tumor mice treated with SS28 (exper-
imental). The experiment was repeated three independent times. Based on the preliminary studies, we selected a 
dose of 15 mg/kg body weight for the investigation. After 12th day of EAC injection, when small sized tumor was 
visible, the animals were treated with nine doses of SS28 (every alternate day). Results showed that there was no 
further tumor progression in the mice when SS28 was administered, unlike the untreated tumor control mice 
(Fig. 7A). Tumor progression was analysed upto 28 days in the study. Therefore, we observed that SS28 treatment 
resulted in inhibition of tumor cell proliferation, although we did not observe complete regression of the tumor.
Effect of SS28 on normal mice. In order to evaluate possible side effects due to SS28 treatment, a total of 
10 BALB/c mice were used. Among them five animals were administered with SS28 (15 mg/kg, 9 doses) while 
other 5 mice were used as tumor control without any treatment. Results showed that there was no significant 
difference in body weight of the animals following SS28 treatment (Fig. 7B). To further check the side effects, we 
performed haematological, liver and kidney function assays. The mice were sacrificed on 21st day of the treatment 
and used for the investigation. Results showed no significant difference in the number of RBCs and WBCs upon 
Figure 5. Effect of SS28 treatment on mitochondrial membrane potential and induction of apoptosis. CEM 
cells were treated with SS28 (1, 5, 10, 20 μ M) for 48 h, harvested and stained with JC-1 dye and analyzed by flow 
cytometry. (A) Upper region represents the healthy cells that emit red fluorescence whereas the lower region 
emits the green fluorescence showing the apoptotic population. 2,4 Dinitrophenol was used as the positive 
control. (B) Bar graphs represent the ratio of red to green fluorescence. (C,D) Annexin V-FITC and PI staining 
to evaluate the effect of SS28 on CEM cells. CEM cells were treated with SS28 and % of apoptotic cells was 
determined by staining with Annexin V-FITC and PI. In each panel, the lower left quadrant shows cells which 
are negative for both PI and Annexin V-FITC, upper left shows only PI cells which are necrotic. The lower right 
quadrant shows Annexin positive cells which are in the early apoptotic stage and the upper right shows the both 
Annexin/PI positive, which are in the late apoptosis necrosis. (C) Control cells and cells treated with SS28 are 
shown. (D) Histogram represents the percentage of early and late apoptotic cells.
www.nature.com/scientificreports/
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treatment with SS28 (Fig. 7C). Further, we found that the ALP level was slightly higher in the treated animals. But 
there was no significant difference in the level of ALT, the marker for normal liver function, upon treatment with 
SS28 (Fig. 7D). Further, there was no significant difference in the levels of creatinine and urea in the serum which 
indicates efficient kidney function (Fig. 7E). Thus, our study indicated that SS28 treatment did not result in any 
major toxicity on functions of normal tissues.
Pharmacokinetics of SS28 in mice models. SS28 was administered intraperitonealy and the concen-
tration of the compound was measured in plasma using a standard plot. Blood was drawn from the heart at 
15 min, 30 min, 1 and 2 h of the administration of SS28. Bioavailability data were obtained by measuring the 
concentration by high-performance liquid chromatography in serum samples taken at different times after SS28 
administration (Fig. 7F). Results showed a significant increase in the level of SS28 in the plasma when collected 
30 min after the injection, although the compound was detectable both at 15 min and 1 h post-treatment (Fig. 7F). 
We observed a significant decrease in the levels of SS28 after 1 h of treatment.
Discussion
Resveratrol, trans-3,5,4′-trihydroxy-trans-stilbene, is a natural polyphenol with potent chemopreventive and 
chemotherapeutic properties9,26. It can modulate multiple cellular processes, including apoptosis, cell cycle pro-
gression, inflammation and angiogenesis26. Moreover, previous studies have shown that hydroxy stilbenes and 
its derivatives can act as potential anticancer agents by targeting microtubule assembly dynamics27,28. In view of 
the cancer preventive and chemotherapeutic property of resveratrol, we synthesised and characterised a series of 
resveratrol derivatives and identified SS28 as a potent anticancer molecule21.
In the present study, we have investigated the mechanism of action of SS28 with its molecular target, Tubulin 
by binding studies in conjunction with the cell based assays, ex vivo and in vivo. We show that SS28 induced 
cytotoxicity in most of the cancer cell lines investigated, in a concentration-dependent manner. SS28 showed only 
limited cytotoxicty on kidney epithelial cell line and PBMCs. SS28 treatment led to G2/M phase arrest in both 
A549 and CEM cells followed by increased accumulation of cells in Sub G1 phase in a time dependent manner 
Figure 6. Expression levels of apoptotic proteins and cell cycle regulatory proteins in A549 and CEM 
cell lines upon treatment with SS28. A549 and CEM cells were treated with SS28 (5 μ M) for 24, 48 and 72 h. 
Whole cell lysate was prepared and proteins were resolved on a SDS-PAGE and western blotting was performed 
using specific primary and secondary antibodies. Blots shown are representative blots of two independent 
experiments with identical results. Actin was used as the loading control. (A) For CEM cells p53, Ku70, Cyclin 
B1, Cdk6, PARP-1, Caspase 9 and Caspase 3 proteins were evaluated. (B) Quantification of the proteins shown 
in panel A is represented as bar diagram with error bars. (C) For A549 cells, p73, Ku80, Cdk6, Cyclin B1, 
Caspase 9 and Caspase 3 proteins were evaluated. (D) Quantification of the respective proteins is shown in bar 
diagram with error bars.
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suggesting activation of cell death pathways following induction of cell cycle arrest. Previous studies have shown 
such a cell cycle arrest by various chemotherapeutic agents. Examples include nocodazole and paclitaxel, both 
targeting microtubule formation resulting in the G2/M cell cycle arrest followed by apoptosis both ex vivo29 and 
in vivo30. Besides, the observed regulation of expression of checkpoint proteins corresponding to the cell cycle 
dynamics can also explain the cell cycle arrest mediated by SS28. Cyclin B1 is known to be involved in G2/M cell 
cycle progression, and is a regulator for G2/M transition31. SS28 treatment led to decrease in the cyclin B1 level 
further explaining the observed cell cycle arrest.
The assembly dynamics of spindle microtubules is crucial for chromosome segregation during mitosis. It has 
been shown that many antimitotic drugs inhibit mitosis at the metaphase/anaphase transition at lower concen-
trations primarily by suppressing microtubule dynamics32–36. We find that SS28 induced disassembly of microtu-
bules with misconfigured chromosomes in A549 cell line. The observed effect is comparable to many other potent 
antimitotic drugs with respect to morphology of spindles in blocked cells1,37,38. Interestingly, we noted that SS28 
treated cells exhibited more distinct structures than the colchicine treated positive controls suggesting that SS28 
has strong affinity to interact with Tubulin in cells, thereby inhibiting the microtubule assembly compared to 
colchicine. Furthermore, the microtubule assembly assay suggests that SS28 inhibits the Tubulin polymerisation 
by binding to Tubulin in a concentration dependent manner.
Docking studies indicated that SS28 can bind to colchicine binding pocket in Tubulin. CD studies revealed that 
SS28 can bind to Tubulin leading to increased molar ellipticity indicating conformational change in protein follow-
ing SS28 binding (Fig. 4A). Besides, fluorescence studies suggested a dissociation constant of 0.414 ± 0.11 μM indi-
cating that the binding affinity of SS28 to Tubulin is comparable to that of colchicine39. Moreover, SS28 exhibited 
an increase in fluorescence upon binding to Tubulin, which was comparable to that known for colchicine40. The 
molecular modeling data showed that methyl benzene group of SS28 can fit in the methoxytropone ring (ring C) 
Figure 7. Impact of SS28 on tumor bearing mouse and evaluation of side effects of SS28 in normal 
BALB/c mice. (A) Nine doses of SS28 (15 mg/kg. b.wt.) were administered orally on every alternate day from 
12th day of EAC cell injection in mice. Data shows volume of tumor measured at different time intervals, with 
and without treatment of SS28. Results depicted from three independent batches of experiments containing 
10 animals each. (B) Mice were orally administered with nine doses of SS28 (15 mg/kg) on every alternate 
day. Data represented as average body weight in both the controls and SS28 treated mice. Error bars indicate 
SEM. (C–E) Hematological profile and renal and liver functional assay. Blood was collected on the 21st day 
of the treatment counted RBC and WBC (C) and serum was tested for alkaline phosphatase (ALP), alanine 
aminotransferase (ALT) (D), urea and creatinine (E). Columns represent mean from five animals in each 
group; bars SEM. (F) Pharmacokinetics of SS28 in mice plasma. SS28 was injected intraperitonealy to mice 
and blood was collected and processed as described in materials and methods. Data represented in time points 
versus the peak area as the function of the concentration of SS28 in plasma.
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of colchicine binding site on Tubulin (Fig. 3C). The results of docking studies were further supported by prelim-
inary competition studies (data not shown). The change in the fluorescence spectra upon addition of SS28 and 
colchicine together indicate the binding of SS28 to the colchicine binding site on Tubulin. In support of this data, 
AC, a colchicine analog, which has A and C ring, which binds to Tubulin rapidly and reversibly to its colchicine 
site shows increase of fluorescence41.
In an earlier study, it has been shown that methylated derivatives of flavonoids exhibit higher antiproliferative 
potency on cancer cells than their hydroxylated counterparts42. In the present study, the small molecule (SS28) 
evaluated is a methoxy derivative of resveratrol exhibiting significant anticancer properties by affecting Tubulin 
proliferation. Increased lipophilic properties of the methoxy derivative of resveratrol can help in increased uptake 
through the cell membrane, besides targeting Tubulin. Our results also support the notion that methylation of the 
hydroxyl groups, could be the critical modification required for interference of Tubulin polymerization.
Annexin V FITC/PI staining showed presence of both early and late apoptotic cells, which increased in a 
dose-dependent manner upon treatment with SS28. However, we did not find cells undergoing necrosis, which 
was also consistent with previous studies using resveratrol based inhibitors. Thus, cytotoxicity induced by SS28 
was mainly due to apoptosis rather than necrosis. Further, the observed reduction in the mitochondrial mem-
brane potential following treatment is consistent with induction of apoptosis by SS28. Caspase family plays a key 
role in apoptosis through the proteolysis of specific targets. Intracellular caspases are activated during apoptosis 
via two major pathways, mitochondria-mediated pathway and death receptor-mediated pathway43. Expression 
analysis showed activation of Caspase 3, Caspase 9 and PARP-1 suggesting activation of intrinsic pathway of 
apoptosis23,43,44.
Our data also showed that SS28 inhibited tumor cell proliferation in mouse bearing EAC tumor. EAC cells 
possessing malignant features of cancer are commonly used for inducing tumors in mice and for evaluating 
anticancer activity of small molecules in vivo45,46. Our results showed that in control animals, the tumor showed 
unrestricted progression, whereas in SS28 treated mice, a significant reduction in the tumor size was observed. 
Hematological and enzymatic assays showed that SS28 did not interfere with other cellular functions. Thus, as 
a proof of principle we show that the novel Tubulin inhibitor identified here inhibits tumor progression in mice 
without major side effects.
Conclusion
In summary, the results of the present study show that SS28, a resveratrol based Tubulin inhibitor can function as 
an antimitotic agent and inhibit cell proliferation in various cancer cell lines. SS28 acts by disrupting the micro-
tubule formation by binding to Tubulin leading to cell death, which is mediated through intrinsic pathway of 
apoptosis in cell lines and mouse tumor tissues. Thus, our results suggest that SS28 can act as a potent microtubule 
targeting agent and further can be developed as an anticancer drug.
Methods
Chemicals and reagents. All the chemicals and reagents used in the present study were obtained from 
Sigma Chemical Co (St. Louis, MO) and SRL (India). Antibodies were purchased from Santa Cruz Biotechnology 
(USA) and Cell Signaling Technology (USA). Purified Tubulin was purchased from MP Biomedicals (France). 
Synthesis and characterization of SS28 [(E)-1,2,3-trimethoxy-5-(4-methylstyryl)benzene (6 h)] has been 
described previously21.
Cell lines and culture conditions. Human T-cell leukemic cell line, CEM; human lung carcinoma cell line, 
A549; Human T-cell leukemic cell line, Molt4; human cervix adenocarcinoma cell line, HeLa; human embryonic 
kidney epithelial cell line, 293T, Mouse embryonic fibroblast (MEF) were purchased from National Centre for 
Cell Science, Pune, India. Human B cell leukemic cell lines, Reh and Nalm6 were a kind gift from Dr. M. Lieber 
and Diffuse large B cell lymphoma cell line, SUDHL8 was a gift from Dr. A. Epstein, USA and PBMC purchased 
from Saarum Biosciences, India. Cells were cultured in RPMI/MEM/Ham’s F12 media 1640 (Sera Lab, USA) 
containing 10% FBS (GIBCO BRL, USA), 100 U of Penicillin G/ml and 100 mg/ml of streptomycin/ml at 37 °C in 
a humidified atmosphere containing 5% CO2.
Molecular modeling of SS28-Tubulin complex. 3D structure of SS28 was generated in Discovery studio 
package using in-built dreiding-like force field (Discovery Studio 4.0. Accelrys, USA). 3D crystal structure of 
α , β -Tubulin bound with colchicine was retrieved from protein databank (PDB ID: 3UT5, www.rcsb.org/pdb)17. 
Molecular docking studies were carried out with Autodock4.2 program47. Briefly, SS28 was docked in colchicine 
binding site keeping the grid centres 9.45, 56.62 and 87.95 for X, Y and Z respectively (npts = 50 for X, Y and Z, 
spacing = 0.375). Rigid docking was carried out using Lamarckian genetic algorithm (GA run was kept 20 with 
medium search parameter). Best pose was selected according to lower binding energy and presented in the final 
image using Pymol.
Circular dichroism. Purified Tubulin (1 μ M) was resuspended in PEM buffer (80 mM PIPES (pH 6.9), 2 mM 
MgCl2, 0.5 mM EGTA, 1.0 mM GTP and 5% glycerol) and CD spectrum was recorded at a wavelength of 200 to 
260 nm (4 °C) on a JASCO J-810 spectropolarimeter. 3 cycles were acquired for each sample at a scan speed of 
100 nm/sec. Increasing concentration of SS28 (500 pM, 1, 10, 100 and 1000 nM) was incubated with Tubulin (1 μ M) 
in PEM buffer and the spectrum was recorded. Spectral measurements were taken for buffer alone and buffer 
containing DMSO were subtracted from experimental data. The molar ellipticity was calculated using Spectra 
Manager software and plotted as a function of wavelength.
Fluorescence polarisation. Fluorescence spectral measurements were performed using Infinite M200 PRO 
microplate reader (Tecan Group Ltd., Switzerland). Briefly, SS28 (10 μ M) was preincubated with increasing 
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concentration of Tubulin (10, 25, 50, 100, 500 and 1000 nM) at 30 °C for 30 min. SS28 Tubulin complex was then 
scanned for the emission spectra from 345 to 545 nm at 315 nm excitation range. Resulting fluorescence intensity 
was plotted as the function of wavelength.
The dissociation constant (Kd) was determined using double reciprocal plot of change in fluorescence of 
SS28 (1/Δ (F0-F)) as a function of protein concentration by the method of Benesi and Hildebrand assuming a 
1:1 binding of SS28 to Tubulin48. The spectral measurements were recorded three times and SEM was calculated.
Cell proliferation assays. The effect of SS28 on viability of CEM, Reh, Nalm6, SUDHL8, Molt4, A549, 
HeLa 293T, mouse embryonic fibroblast (MEF) and PBMC was determined by trypan blue dye exclusion assay 
as described previously49,50. Briefly, cells (0.75 × 105 cells/ml) were treated with increasing concentrations of SS28 
(1, 5, 10 and 20, μ M) for 48 and 72 h. DMSO treated cells were used as the vehicle control. Cells were harvested 
and subjected to trypan blue assay. Data from a minimum of three independent experiments is presented as a 
histogram with error bars.
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay was performed to determine the 
effect of SS28 on proliferation of cells as described51,52. Briefly, CEM, Reh, Nalm6, SUDHL8, Molt4, A549, HeLa 
and 293T cells (0.5 × 105 cells/ml) were seeded in 24 well plate and treated with increasing concentrations of SS28 
(1, 5, 10, 20 μ M). MTT assay was performed after 48 and 72 h of incubation. The absorbance of experimental 
samples were divided by absorbance of untreated control, and presented as % of inhibition and shown as a bar 
diagram. DMSO treated cells, served as vehicle control. Error bars were calculated based on a minimum of three 
independent experiments and data is presented as histogram.
Cell cycle phase distribution. Cell cycle analysis by flow cytometry was performed as previously 
described53. Briefly, 75,000 cells/ml (A549) were seeded in 6 well plates and grown in serum free medium for 18 h. 
After synchronisation, the cells were treated with 5 μ M of SS28 (6, 12, 18, 24 and 30 h) and cells were processed as 
described before53,54. Similarly, CEM cells (75,000 cells/ml) were treated with SS28 (2 μ M) and harvested (6, 12, 
18, 24 and 30 h) and processed. Following fixation, cells were resuspended in PBS and stained with propidium 
iodide and evaluated in a flow cytometer (FACS Calibur, Becton Dickinson) using Cell Quest Pro software using 
excitation 488 nm laser and emission at 560/570 nm. A minimum of 10,000 cells were acquired per sample and 
histograms were analysed using WinMDI 2.8 software.
Annexin V-FITC/PI double-staining assay. When cells undergo apoptosis, the integrity of the cell mem-
brane is disrupted and phosphatidyl serine is exposed. Annexin V conjugated with FITC (apoptosis detection kit 
Santacruz, USA) has a selective affinity for phosphatidyl serine, based on which early and late apoptotic cells can 
be detected.
CEM cells (1 × 105 cells/ml) were treated with SS28 (5 and 10 μ M) for 48 h. Cells were then harvested, washed 
with cold PBS and used for annexin-PI double-staining assay55,56. Samples were resuspended in 1x binding buffer 
and incubated with Annexin V-FITC (0.4 g/μ l) and PI (0.05 mg/ml) and analyzed by flow cytometry (FACS cal-
ibur) using CellQuest pro software at an excitation with 488 nm laser and emission at 530 nm55. A minimum of 
10,000 cells were acquired for each sample and illustrated as dot plot using Flowing software.
Determination of mitochondrial transmembrane potential. Flow cytometric analysis of cells stained 
with JC-1 was used to measure changes in mitochondrial transmembrane potential as described49,56. Briefly, cells 
were seeded at a density of 1 × 105 cells/ml and treated with SS28 (1, 5, 10 and 20 μ M). After 48 h, cells were 
harvested, washed and incubated with JC-1 (5,5′,6,6 tetrachloro-1,1′,3,3′-tetraethyl benzimidazol carbocyanine 
iodide; Calbiochem, USA) for 15 min. 2,4-Dinitrophenol-treated cells (2,4-DNP) served as the positive control. 
Cells were processed and analyzed by flow cytometry using CellQuest pro software with an excitation at 488 nm 
laser and emission at 530 nm. JC-1 monomers emit at 530 nm and J-aggregates emit at 590 nm.
Assay for intracellular ROS production. Intracellular ROS generation in cells was assessed using the 
oxidation-sensitive fluorescent probe 2,7-dichlorodihydro fluorescein diacetate (H2DCFDA) as previously 
described52,57. CEM cells were treated with SS28 (5 μ M) for 5, 10, 15, 30 and 60 min, harvested, washed and incu-
bated with H2DCFDA (30 min at 37 °C) and then fluorescence intensity was analyzed by flow cytometry. H2O2 
was used as the positive control.
Immunofluorescence microscopy. Immunofluorescence microscopy was performed as previously 
described51,58. A549 cells were grown on coverslips coated with gelatin (0.1%). Cells were treated with SS28 (5 μM, 24 h) 
and were fixed with 2% p-formaldehyde (20 min at RT). After 24 h of the treatment nonspecific antibody bind-
ing sites were blocked using FBS following which cells were incubated with antitubulin antibody (1:500) at RT. 
Coverslips were washed in PBS, incubated in biotinylated antimouse secondary antibody (1:500; RT for 1 h) fol-
lowed by Streptavidin-FITC (1:200). Finally, cells were mounted with DABCO and images were captured using 
Zeiss Fluorescence microscope and analyzed using Axio vision software. Colchicine treated cells were used as a 
positive control.
Microtubule assembly assay. Separation of insoluble polymerized Tubulin from soluble Tubulin dimers 
was performed as described59. In brief, CEM cells (1 × 106) were treated with 2, 5 and 10 μ M of SS28 for 24 h. Cells 
were harvested and washed with PBS before adding polymerization lysate buffer containing 20 mM Tris-HCl 
(pH 6.8), 1 mM MgCl2, 2 mM EGTA, 20 g/ml aprotinin, 20 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 
1 mM orthovanadate and 0.5% NP-40. After centrifugation of the lysates at 15,000 × g for 10 min at 4 °C, the pel-
lets were resuspended in SDS-PAGE loading buffer and dissolved by heating at 95 °C for 10 min. α -Tubulin was 
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then immunoblotted for the pellet fraction containing polymerized microtubules and supernatants containing 
depolymerised microtubules were equalised and resolved on 8% SDS PAGE.
Immunoblotting. Cell lysate was prepared after treating with SS28 (5 μ M for 24, 48 and 72 h) from CEM and 
A549 cell lines58,60. In brief, cells were harvested, washed with PBS, resuspended in lysis buffer (RIPA, 25 mM Tris 
(pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) containing protease inhibitors. The 
protein lysate was cleared by centrifugation (14,000 rpm, for 15 min). The protein concentration in the superna-
tant was determined using the Bradford’s assay.
For western blot analysis, ~40 μ g proteins were resolved over 8–10% SDS–polyacrylamide gel60–62. Following 
gel electrophoresis, proteins were transferred to PVDF membrane (Millipore, USAQ9). The primary antibodies 
used were against Caspase 3, Caspase 9, p73, p53, KU70, KU80, Cyclin B1, CDK6, PARP1 and Actin (Santa Cruz 
Biotechnology, USA). The membrane was incubated with appropriate HRP-conjugated secondary antibody (2 h at 
4° C). The blots were developed using chemiluminescent solution (ImmobilonTM western, Millipore) and scanned 
by gel documentation system (LAS 3000, FUJI, Japan). Blots were stripped subsequently as per standard protocols 
and reprobed with anti β -Actin antibody.
In vivo experiments. Animals. All the animal experiments were performed as per the principles and guide-
lines of the ethical committee for animal care of Indian Institute of Science (IISc) in accordance with Indian National 
Law on animal care and use. The Institutional Animal Ethics Committee of Indian Institute of Science, Bangalore, 
India approved the experimental design of the present study (Ref. CAF/Ethics/288/2012). BALB/c mice, 8–10 week 
old, weighing 18–22 g were purchased from central animal facility, IISc, India and used for the study. The animals 
were housed in polypropylene cages and provided standard pellet diet (Agro Corporation Pvt. Ltd., Bangalore, 
India) and water ad libitum. The standard pellet diet is composed of 21% protein, 5% lipids, 4% crude fiber, 8% ash, 
1% calcium, 0.6% phosphorus, 3.4% glucose, 2% vitamin, and 55% nitrogen-free extract (carbohydrates). The mice 
were maintained under controlled conditions of temperature and humidity with a 12 h light/dark cycle.
Preparation of Ehrlich ascites carcinoma (EAC) cells for induction of tumor. EAC cells were collected from donor 
mice (Swiss albino) and resuspended in sterile saline. A fixed number of viable cells were injected into the perito-
neal cavity of each recipient mouse and were allowed to multiply. The cells were withdrawn, diluted in saline and 
injected (15 × 105 cells/animal) into the right thigh tissue of experimental animals for developing solid tumor.
Evaluation of antitumor activity of SS28 in mice models. A total number of 30 BALB/c mice were divided into 
three batches and were used for the present study. EAC cells (15 × 105 cells/animal) were injected into right thigh 
for the development of solid tumor as described previously57,61,63. Among the 10 animals in each batch, 5 animals 
served as tumor control and the rest 5 animals received SS28 treatment (15 mg/kg b.wt.) by oral administration 
using gastric gavage. The dose used was selected based on preliminary studies. The first dose was given after 12th 
day of tumor development (9 doses over a period of 3 weeks). The diameter of developing tumor was measured 
using vernier calipers at alternative days for entire life span of tumor animal and tumor volume was calculated 
using the formula V = 0.5 × a × b2, where “a” and “b” indicates the major and minor diameter, respectively61.
Evaluation of toxicity of SS28 in normal mice. A total number of 10 BALB/c mice were used for the study, of 
which 5 animals served as normal control while, remaining 5 were treated with SS28 (15 mg/kg). Body weight of 
each animal was monitored throughout the experiment and average body weight was calculated on 21st day of 
treatment. In order to evaluate the effect of SS28 on physiological functions, blood was collected (21st day) and 
analysed as described earlier61. The blood plasma was analyzed using Neubauer’s chamber, and mean values of 
total red blood cells (RBCs) and white blood cells (WBCs) were determined. Serum was separated and kidney 
and liver function tests were performed for each animal, to determine alkaline phosphatase (ALP), alkaline trans-
ferase (ALT), creatinine and urea levels as described earlier61. Values are presented as mean ± SEM for both the 
controls and SS28 administered mice.
In vivo pharmacokinetics study. HPLC analysis of serum. Control and SS28 (15 mg/kg b.wt.) treated 
BALB/c mice were sacrificed and blood was collected at various time points (15, 30 min, 1 and 2 h; 2 each/time 
point) as described9,26. Plasma (50 μ l) was then extracted with acetonitrile, centrifuged (3,000 × g for 15 min) to 
remove precipitated proteins and the resulting supernatants were analyzed using HPLC (Waters, USA).
Standard solution of SS28 was prepared by dissolving increasing concentration (25 to 100 μ M) of the com-
pound in acetonitrile. Standard calibration curves were plotted using peak area against the concentration of the 
compound and the retention time of the compound was also determined. Plasma concentrations of the treated 
groups were extrapolated from standard curves constructed by linear regression in Graph-Pad Prism 4.0 software 
(GraphPad Software, Inc.).
Statistical Analysis. As specified, values in tables and figures are expressed as the mean ± SEM of two to three 
independent experiments. Statistical comparisons were made by one-way ANOVA followed by Student’s t test 
using Graph-Pad Prism 4.0 software (GraphPad Software, Inc.). A probability value of < 0.05 was considered to 
be significant.
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